Curis (CRIS -4.5%) trades rather violently after the FDA approves Erivedge for use to treat...

|By:, SA News Editor

Curis (CRIS -4.5%) trades rather violently after the FDA approves Erivedge for use to treat adult patients with skin cancer. Shares spiked up 7%, then sank 14% before quickly heading back north.